Efficacy and Safety Trial of MK-8931 in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Diseases and Conditions Researched

Alzheimer's Disease; Amnestic Mild Cognitive Impairment; Prodromal Alzheimer's Disease

What is the purpose of this trial?

The purpose of this trial is to assess the efficacy and safety of MK-8931 compared with placebo in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants will be randomized to receive placebo, or 12 mg or 40 mg MK-8931, once daily. The primary study hypothesis is that at least one MK-8931 dose is superior to placebo with respect to the change from baseline in the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB) score at 104 weeks.


Participation Guidelines

Age: 50 Years - 85 Years
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Merck Sharp & Dohme
Dates:
Last Updated:
Study HIC#: 1309012771